Stockscreener 앱 받기
61.74
0.65%
0.40
시간 외 거래:
61.95
0.21
+0.34%
전일 마감가:
$61.34
열려 있는:
$61.11
하루 거래량:
628.80K
Relative Volume:
1.04
시가총액:
$3.80B
수익:
$112.53M
순이익/손실:
$-258.91M
주가수익비율:
-14.26
EPS:
-4.33
순현금흐름:
$-124.42M
1주 성능:
+6.76%
1개월 성능:
+17.96%
6개월 성능:
+20.99%
1년 성능:
+60.57%
1일 변동 폭
$60.92
$61.96
1주일 범위
$56.12
$62.83
52주 변동 폭
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
RYTM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
61.74 | 3.80B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results - markets.businessinsider.com
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - MSN
Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus
Canaccord maintains Buy on Rhythm Pharma following Ph3 data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Target Price Raised by BofA Amid P - GuruFocus
Rhythm Pharmaceuticals EVP Yann Mazabraud sells $1.08 million in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) Surges on Nasdaq Rebound - GuruFocus
Rhythm Pharmaceuticals Stock (RYTM) Erases YTD Losses This Week - AskTraders.com
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target By Investing.com - Investing.com Canada
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - MSN
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade - MSN
Rhythm’s setmelanotide cuts BMI by 20% - The Pharma Letter
Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug - TradingView
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $77 From $72, Keeps Overweight Rating - MarketScreener
Canaccord raises Rhythm Pharma stock target to $92, maintains buy - Investing.com
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target - Investing.com
Rhythm Pharmaceuticals shares rise on raised target to $80 By Investing.com - Investing.com UK
Canaccord raises Rhythm Pharma stock target to $92, maintains buy By Investing.com - Investing.com Canada
Positive Phase 3 Results and Market Potential Boost Rhythm Pharmaceuticals’ Price Target - TipRanks
BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 - Investing.com Australia
Rhythm Pharmaceuticals (RYTM) Surges as Obesity Drug Achieves Ke - GuruFocus
Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway - MedCity News
Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success - insights.citeline.com
Rhythm Pharmaceuticals’ Bold Moves: What’s Next? - timothysykes.com
Rhythm Pharmaceuticals price target raised to $77 from $72 at Morgan Stanley - TipRanks
Rhythm posts late-stage trial win for lead asset against rare form of obesity - MSN
Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish - MSN
BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 By Investing.com - Investing.com Canada
Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ) - Seeking Alpha
Rhythm Pharmaceuticals (RYTM) Achieves Success in Phase 3 Obesit - GuruFocus
Rhythm Pharmaceuticals Plans Regulatory Filings After Positive I - GuruFocus
Why Rhythm Pharmaceuticals Stock is Climbing High - TipRanks
Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder - Yahoo
Rhythm Pharmaceuticals’ Unexpected Surge: A Stock to Watch? - timothysykes.com
Rhythm Pharma's drug for rare obesity meets late-stage trial goal - MSN
Rhythm Pharmaceuticals (RYTM) Reports Promising Phase 3 Trial Re - GuruFocus
Rhythm Pharmaceuticals (RYTM) Achieves Phase 3 Trial Success wit - GuruFocus
Rhythm Pharmaceuticals stock rises on trial success By Investing.com - Investing.com India
Rhythm Pharmaceuticals stock rises on trial success - Investing.com Australia
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in trial - MSN
Rhythm Pharmaceuticals' Obesity Treatment Meets Main Goal in Phase 3 Study, Shares Rise - MarketScreener
Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction In Patients (N=120) With Acquired Hypothalamic Obesity - MarketScreener
Rhythm Pharmaceuticals Announces Positive Phase 3 Trial Results - TipRanks
Rhythm Pharmaceuticals says Phase 3 TRANSCEND trial meets primary endpoint - TipRanks
Rhythm Pharma Reports Positive Topline Results From Phase 3 TRANSCEND Trial With Setmelanotide - Nasdaq
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial - MarketScreener
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity - GlobeNewswire
Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint with -19.8% - MarketScreener
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rhythm Pharmaceuticals Inc 주식 (RYTM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cramer Pamela J. | Chief Human Resources Officer |
Apr 08 '25 |
Sale |
60.14 |
20,760 |
1,248,490 |
19,209 |
| Mazabraud Yann | EVP, Head of International |
Apr 08 '25 |
Sale |
60.99 |
17,750 |
1,082,497 |
22,620 |
2.51%
자본화:
|
볼륨(24시간):